Lipodystrophy syndromes are a heterogeneous group of disorders associated with selective absence of fat. Currently, the diagnosis is established only clinically.
-Fat shadows derived from DXA scans of patients with lipodystrophy and selected control subjects. A: Patients with CGL have minimal fat signal on the fat shadow. CGL type 2 (i) was associated with no visible residual fat depots, whereas CGL type 1 (ii) is seen to have residual fat in the periauricular area and soles and in females the labial region. B: Male (i) and Female (ii) acquired GL patients are shown. They have no subcutaneous fat depots throughout their body, with minimal fat signal visible in the scan. C: The two classic presentations of different FPLD subtypes. FPLD2 (Dunnigan variety; i and ii) typically presents with the same signature phenotype with absence of subcutaneous fat in the extremities, hips, and abdomen (flanks), along with a hypertrophy in the neck, axillae, and mons pubis. Dunnigan sign was defined as the isolated high signal area corresponding to the mons pubis, surrounded by profound subcutaneous (sc) lipoatrophy. This sign was found to be helpful in identifying patients with FPLD2 and also evident in the one male with FPLD2 present in this cohort (i). Increased fat signal around the mons pubis region was present in all 21 (100%) FPLD2 females versus only were all previously enrolled into various clinical studies in which measurement of adiposity was of interest, and total body composition scans were obtained. All participants were seen at either the Michigan Clinical Research Unit (Michigan cohort) or the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Intramural Research Program (National Institutes of Health [NIH] cohort) from 2007 to 2017 and had consented to participate in the research studies with permission to use their data in future studies. Patients with lipodystrophy were diagnosed clinically, which is the reference standard (3). Control subjects were selected to match age and fat-free mass index from the Michigan archives. At the NIDDK, control subjects were selected to match age, sex, and BMI.
Developing the Fat Shadow Method
Our objective was to find a way to visualize the information on fat distribution captured by DXA in a clinically useful way that conveys the overall fat distribution pattern. Body composition scans were acquired on a Prodigy table at the Michigan site and an iDXA table at the NIH site, both of which were DXA systems manufactured by GE Lunar (Chicago, IL). Scan files (.dfb for Prodigy and .meb for iDXA) were analyzed using enCORE v14.10. Visualization options available through the built-in functions of the software were evaluated in depth to find potentially useful modalities (Supplementary Fig. 1 ). A composition map colorcoded to render out the nonfat tissues highlighted the overall fat distribution ( Supplementary Fig. 2 ). The resulting image was termed a fat shadow, as it corresponded to the X-ray shadow of fat tissues.
Evaluation of Fat Shadows and Validation of Diagnostic Accuracy
First, the fat shadows available at Michigan were explored qualitatively in an unblinded fashion to identify clinically relevant features and count their frequencies in different subtypes. The method was then validated in a blinded, retrospective study. Both the Michigan and NIDDK sites compiled their scans for case and control subjects and removed all identifiers. For the first step of validation in familial partial lipodystrophy (FPLD), scan files from NIDDK were transferred to Michigan, where the images were rendered. For the second step, rendered images from the Michigan cohort were sent to NIDDK to be assessed by NIH investigators after reviewing a training deck. For the third step of validation, an independent investigator evaluated all cases from both cohorts after first reviewing the training deck. For validation of the method in GL, the independent investigator evaluated a compilation of all GL scans and nonobese control subjects. Training cases were excluded from all assessments. The only information shown in addition to the fat shadow was sex. In steps one and two, two investigators evaluated the images independently and reached a consensus in case of disagreement. Investigators identified the FPLD type 2 (FPLD2) from other FPLD (FPLDX) as an exploratory end point. CIs for sensitivity and specificity were derived with the Clopper-Pearson method. Agreement rates were calculated using Cohen k.
RESULTS
The Michigan cohort included 48 patients with lipodystrophy (41 female and 7 male, aged 13-65 years), 43 of whom had FPLD, and 70 control subjects (42 female and 28 male, aged 19-65 years). The NIH cohort included 13 patients with GL (9 female and 4 male, aged 14-40 years), 14 patients with FPLD (12 female and 2 male, aged 18-65 years), and 56 control subjects (48 female and 8 male, aged 18-65 years). Supplementary Tables 1  and 2 list all of the subtypes, demographic characteristics, and average body composition characteristics of both cohorts.
Overall, patients with lipodystrophy had uniquely different fat shadows compared with control subjects. Patients with GL had a striking appearance with nearcomplete absence of fat signal ( Fig. 1A and B). Residual fat depots were seen in the periauricular area, soles, and pubic region in some patients with congenital generalized lipodystrophy (CGL) type 1. Patients with acquired GL (two females and two males) had no visible residual fat. Figure 1C compares the typical presentations of FPLD2 and FPLDX (specifically, FPLD1, Köbberling variety [9] ). Presentation of FPLD2 followed a relatively consistent pattern ( Supplementary  Fig. 3) , with subcutaneous fat absent throughout the body in most patients, but with hypertrophic fat in the neck and pubic region. In contrast, the FPLDX population was very heterogeneous ( Supplementary Fig. 4 ). Images from patients with acquired partial lipodystrophy showed very little fat in the upper half of the body, whereas the fat depots in the hips and lower extremities were preserved or even hypertrophic (Fig. 1D ). Obese and lean control subjects are shown in Fig. 1E for comparison. Supplementary Tables 3 and 4 show the frequency of different features in each subtype organized into different sex categories. The Fat Shadow Atlas in the Supplementary Data demonstrates the fat shadows of all participants used in this study.
Accuracy of the method is presented in Supplementary Table 5 . FPLD was differentiated from control subjects with 85% sensitivity and 96% specificity (95% CIs 72-93 and 91-99, respectively). GL was differentiated from nonobese control subjects with 100% sensitivity and specificity (95% CIs 79-100 and 92-100, respectively). The k for interobserver agreement rates ranged between 0.73 and 0.96 (Supplementary Table 6 ). Some subtypes were recognizable from their fat distribution patterns (Supplementary Table 7 ).
CONCLUSIONS
This study shows that fat shadows derived from DXA scans are simple tools to diagnose lipodystrophy syndromes. Various quantitative measurements from DXA scans have been used in lipodystrophy research (5, (10) (11) (12) ; however, these measurements were done in regions of interest that were too broad and not necessarily designed to be clinically relevant in the context of lipodystrophy ( Supplementary Fig. 5 ). This study is the first to use DXA body composition scans to diagnose disease in a pixel-based approach. Using this technique, investigators were able to identify patients with both GL and partial lipodystrophy accurately.
Metreleptin was approved in 2014 as the first therapy for GL (13). This therapy, although very helpful for the treatment of difficult metabolic complications, is currently very expensive in the U.S., and third-party payers require verification of the diagnosis with genotype even when insurance coverage for genetic testing may not be provided. When genetic testing is not feasible or negative, having the ability to document the body fat pattern with the fat shadow method may aid complicated therapeutic decisions. FPLD has also recently attracted attention from industry with development of novel therapeutic agents; however, the U.S. Food and Drug Administration has expressed concern about whether this phenotype is sufficiently distinct from truncal obesity or common metabolic syndrome (14). We believe that our data add to the evidence that FPLD covers a spectrum of heterogeneous diseases with unique fat distribution patterns that are distinct from common forms of truncal obesity. It may prove useful not only in drug reimbursement decisions, but also for adjudication of cases for drug trials or other different clinical settings.
Our study had a number of limitations listed in Supplementary Table 8 and is only the first step to bring this tool to clinic. However, the tool has substantial strengths over other methods, which are also listed. This method can be further enhanced with standardization and by adding lateral views, as proposed in Supplementary Fig. 6 . With further studies, it may be possible to use fat shadows for classification of not only lipodystrophy but also other metabolic diseases.
